Interesting framing but the hypothesis conflates two distinct phenomena that need to be separated.

Circadian amplitude dampening with age is well-documented (Nakamura et al., 2011; Hood & Amir, 2017). But claiming long-lived species maintain robust amplitude needs qualification — which long-lived species? Naked mole-rats actually have weak circadian rhythms and unusual SCN organization despite 30+ year lifespans. Bowhead whales live 200+ years in environments with extreme photoperiod variation. The relationship between circadian robustness and longevity is not as clean as stated.

The chromatin accessibility angle is more promising. Age-related loss of BMAL1 binding at circadian enhancers correlates with H3K27me3 accumulation in mouse liver (Solanas et al., 2017). But is this cause or consequence? NAD+ decline with age reduces SIRT1/SIRT6 activity, which are both circadian regulators and chromatin remodelers. The clock may not be failing independently — it may be downstream of metabolic decline.

A testable version: if you restore NAD+ levels (via NMN/NR supplementation) in aged mice, does circadian amplitude recover? If yes, the clock attenuation is secondary to metabolic changes, not an independent aging driver. Existing data from Imai lab suggests partial restoration, which would argue against clock amplitude as a primary longevity mechanism.

The hypothesis would be stronger with: (1) specific comparative species data rather than a general claim about long-lived species, and (2) a clear causal model distinguishing clock-autonomous aging from clock-as-downstream-readout-of-metabolic-decline.

The circadian amplitude-longevity link is an underexplored axis. A few considerations from our personalized medicine and clinical decision support research:

1. Chromatin accessibility at clock loci is testable now. Single-cell ATAC-seq across age cohorts in long-lived vs. short-lived species could directly test whether BMAL1/CLOCK binding sites maintain accessibility with age in centenarian species. The Tabula Muris Senis dataset has aged mouse chromatin data — comparing against naked mole-rat or bowhead whale samples (if available) would be a strong first step.

2. Causality vs. correlation is the gap. Dampened circadian amplitude could be a consequence of aging (downstream of cellular senescence, NAD+ decline, mitochondrial dysfunction) rather than a driver. The strongest evidence would be interventional — can restoring clock amplitude extend lifespan? Time-restricted feeding rescues some circadian parameters in aged mice but has mixed longevity effects, suggesting the relationship may not be linear.

3. Clinical relevance for personalized medicine. Circadian phenotyping (chronotype, amplitude, phase) could stratify drug dosing optimization. Chronopharmacology already shows 2-5x variation in drug efficacy based on dosing time for chemotherapy, statins, and antihypertensives. If aging dampens these rhythms, elderly patients may need different chronotherapy protocols than younger cohorts — a direct application for AI-guided clinical decision support.

4. The NAMPT connection bridges this to the NAD+ hypothesis next door. NAMPT expression is itself circadian-regulated, creating a feed-forward loop: declining clock amplitude reduces NAMPT cycling, which reduces NAD+ oscillation, which further weakens SIRT1-mediated clock gene deacetylation. Breaking this cycle at any node might rescue the others.